Literature DB >> 1393335

The Scottish first episode schizophrenia study. VIII. Five-year follow-up: clinical and psychosocial findings. The Scottish Schizophrenia Research Group.

.   

Abstract

Forty-four schizophrenic patients were followed up for five years after their first admission to hospital for a first episode of illness. Thirteen (30%) of 43 patients had not relapsed; 28 of the 30 patients who did relapse did so within the first 42 months. The relapses occurred despite antipsychotic drug therapy. Also, 24% of patients had at least one course of ECT. Only 19% of the patients at five years were in open employment; unemployment was strongly associated with relapse. Eighteen per cent had neither relapses nor schizophrenic symptoms at follow-up. Poor outcome at five years was associated with greater psychological distress among relatives at first admission. At five years 43% of relatives continued to show case level psychological stress.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1393335

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  19 in total

1.  Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study.

Authors:  Yu-Tao Xiang; Chuan-Yue Wang; Yong-Zhen Weng; Qi-Jing Bo; Helen F K Chiu; Sandra S M Chan; Edwin H M Lee; Gabor S Ungvari
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-11-03       Impact factor: 4.328

2.  Predicting caregiver burden in first admission psychiatric patients. 2-year follow-up results.

Authors:  Anne Maria Möller-Leimkühler; Michael Obermeier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-20       Impact factor: 5.270

Review 3.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 4.  Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

5.  Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis.

Authors:  J F Guest; R F Cookson
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 6.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

7.  Work therapy for schizophrenic patients: results of a 3-year prospective study in Germany.

Authors:  T Reker; B Eikelmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

8.  Multivariate prediction of relatives' stress outcome one year after first hospitalization of schizophrenic and depressed patients.

Authors:  Anne Maria Möller-Leimkühler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-04       Impact factor: 5.270

9.  Effects of a psychoeducational intervention program on the attitudes and health perceptions of relatives of patients with schizophrenia.

Authors:  José Gutiérrez-Maldonado; Alejandra Caqueo-Urízar; Marta Ferrer-García
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-11-03       Impact factor: 4.328

10.  Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.